Clinical trial
A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen
NCT00135395
Study timeline
Study start (unknown)2004-05-01Date precision: month
Registry last updated2010-02-05
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
HIV Infectionsunresolved
Interventions
Sponsors & collaborators
Bristol-Myers Squibblead sponsor
Mapped research locations
New YorkNew York, United States1HoustonTexas, United States1BostonMassachusetts, United States1ChicagoIllinois, United States1Los AngelesCalifornia, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1St LouisMissouri, United States1AtlantaGeorgia, United States1MiamiFlorida, United States1San FranciscoCalifornia, United States1TampaFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00135395 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.